title: Differential modulation of intracellular Ca2+ responses in B lymphoblasts by mood stabilizers.
abstract: Irregularities of intracellular calcium (Ca2+) homeostasis have been implicated in the pathophysiology of bipolar disorder (BD). Findings that chronic ex-vivo treatment with lithium modifies lysophosphatidic acid (LPA)-stimulated Ca2+ responses in B lymphoblast cell lines (BLCLs) from BD-I patients and healthy controls, and differentially decreases levels of the type-3 canonical transient receptor potential Ca2+-permeable channel in BLCLs from BD-I patients, support the view that the amelioration of these abnormalities is important in the therapeutic action of lithium. To determine whether other clinically efficacious mood stabilizers share these effects, LPA (100 mum)- and thapsigargin (TG, 200 nm)-stimulated Ca2+ responses were determined in BLCLs from BD-I patients and healthy controls treated acutely (24 h) and chronically (7 d) ex vivo with therapeutically relevant concentrations of lithium (0.75 mm), valproate (0.5 mm), lamotrigine (15 mum) or respective vehicles. Chronic treatment with valproate significantly attenuated LPA-stimulated Ca2+ responses ([downward arrow]8%: F's=9.1-9.4, d.f.=1, 9, p's<0.05) compared to vehicle in BLCLs from BD-I patients and healthy controls, similar to chronic lithium treatment ([downward arrow]8%: F=6.2, d.f.=1, 21, p<0.05), but also attenuated TG-evoked Ca2+ responses ([downward arrow]10% to [downward arrow]19%: F's=5.5-15.5, d.f.=1, 12, p's<0.05). However, chronic lamotrigine treatment did not affect LPA- or TG-stimulated Ca2+ responses. These results suggest that chronic lithium and valproate treatments act differently from lamotrigine in respect of modulation of receptor- and/or capacitance-mediated Ca2+ flux. These differential effects on Ca2+ responses may be relevant to the distinctive clinical profiles of these mood stabilizers.
authors.affiliation: Laboratory of Cellular and Molecular Pathophysiology, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Perova
authors.forename: Melodie
authors.initials: M
authors.lastname: Kwan
authors.forename: Peter P
authors.initials: PP
authors.lastname: Li
authors.forename: Jerry J
authors.initials: JJ
authors.lastname: Warsh
mesh_terms: D000328:Adult; D018692:Antimanic Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001714:Bipolar Disorder / Q000473:pathology; D002118:Calcium / Q000378:metabolism*; D002461:Cell Line, Transformed; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D007424:Intracellular Fluid / Q000187:drug effects* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D018021:Lithium Chloride / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D019284:Thapsigargin / Q000494:pharmacology; D014635:Valproic Acid / Q000494:pharmacology
chemical_list: D018692:Antimanic Agents; D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D014635:Valproic Acid; D019284:Thapsigargin; D018021:Lithium Chloride; D002118:Calcium